Close Menu

NEW YORK – Adaptive Biotechnologies announced Thursday that it has received expanded clearance from the US Food and Drug Administration for its clonoSeq assay to assess minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL.)

The next-generation sequencing-based test can now be used to detect and monitor MRD from blood or bone marrow samples and is the first and only FDA-cleared in vitro diagnostic for MRD monitoring in CLL, the firm said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.